natgillin/translations-raw huggingface dataset:
A compound according to claim 19 having the formula (II): wherein the group A is attached to the meta or para position of the benzene ring and q is 0-4. 
RLZNOR N-N H a pri čemu je skupina A spojena u meta ili para položaju prstena benzena i q je 0-4.
• providing a compound of formula II: wherein 
* pripremu spoja formule II: Mpa-OH
The node 2 generates a message S 2 which contains a time stamp signal TS coinciding with the occurrence of another reference point T+ in the phase voltage of the wiring phase T of node 2 . 
- < odašiljanje od spomenute relejne lokacije relejnog vremenskog otisnutog signala (S2, TS) kada se pojavi referentna točka (T+) u spomenutom faznom naponu vodiča (T) spomenute relejne lokacije (2);
The solid support of claim 1, wherein the solid support is a population of microparticles, and the first polynucleotide is immobilized at its 5' end to the surface of the microparticle and the second polynucleotide is hybridized to the 3' end of the first polynucleotide. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se 3’ terminalni slijed transposona prvog polinukleotida prebacuje na 5’ krajeve oba lanca fragmentirane ciljane dvolančane DNA.
The formulation for use according to claim 4 wherein the formulation comprises a capsule and the total dose of the compound of formula (I) administered to the subject is 200 mg a day. 
Formulacija za primjenu u skladu sa patentnim zahtjevom 4 pri čemu formulacija sadrži kapsulu i ukupna doza spoja sa formulom (I) administrirana subjektu je 200 mg na dan.
Example 11: Crystallization of donepezil hydrochloride form IV g donepezil hydrochloride was suspended in isopropanol (6 ml) and 1 ml of water, heated to reflux to get a clear solution. 
Primjer 11: Kristalizacija donepezil hidroklorida oblika IV 1 g donepezil hidroklorida suspendiran je u izopropanolu (6 mL) i 1 mL vode, te zagrijavan u refluksu s ciljem dobivanja bistre otopine.
A combination for use according to claim 5 wherein the B2 agonist is formoterol fumarate. 
Kombinacija sukladno patentnom zahtjevu 4, naznačena time, da je kortikosteroid beklometazon dipropionat.
For each cell recorded, a glass coverslip containing the cells was placed at the bottom of a Perspex chamber containing bath solution (sec below) at room temperature (˜20° C.). 
Za svaku snimanu stanicu, stakalce sa stanicama je postavljeno na dno Perspex komorice koja je sadržavala otopinu za kupku (vidi dolje) pri sobnoj temperaturi (-20 *C).
at least 40 °C for a period of at least six weeks, or 
(a) najmanje 40 "€ kroz razdoblje od najmanje šest tjedana, ili
In the case of the field trials, application was effected with the aid of a mobile plot sprayer. 
U slučaju ispitivanja na polju, primjena se postiže uz pomoć pokretne prskalice.
Antimicrobial and vulnerary pharmaceutical composition for external application containing antibiotic fosfomycin as a therapeutic agent, characterized in that it is prepared in form of powder and contains finely dispersed nanostructured silica dioxide in the weight ratio fosfomycin: finely dispersed nanostructured silica dioxide of (25-75% by weight): (75-25% by weight). 
HR P20150112 T1 PATENTNI ZAHTJEVI Antimikrobni farmaceutski sastav za rane za vanjsku primjenu koji sadrži antibiotik fosfomicin kao terapeutski agens, naznačen time što je pripravljen u obliku praška i sadrži fino raspršen nanostrukturirani silicijev dioksid u težinskom omjeru fosfomicin: fino raspršen nanostrukturirani silicijev dioksid od (25-75% težinski): (75-25% težinski).
and R20 are each independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; and n is 1, 2, or 3. 
i R20 su neovisno vodik, alkil, supstituirani alkil, aril ili supstituirani aril;
The composition according to either of Claims 4 or 5, wherein said composition is suitable for inhalation. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1-11, gdje je sastav pogodan za inhalaciju.
The fractions were pooled based on HPLC analysis and evaporated to yield 39.3 g (98.6 area percent) of 2′-O-TBDMS-10-deacetyl paclitaxel solid of Formula 3 (where R1═R2═Ph; P1=TBDMS in generalized formula C of Scheme 1). 
Frakcije su bile sakupljene pomoću HPLC analize 1 uparene da bi se dobilo 39.3 g (98.6 prostornih postotaka) krutine 2'-O-TBDMS-10-deacetil paklitaksela formule 3 (gdje Ri=R2=Ph; P,=TBDMS u općoj formuli C iz sheme 1).
The method of Claim 1 wherein the parasitic invertebrate pest is a fly, mosquito, mite, tick, louse, flea, true bug or maggot, preferably wherein the animal to be protected is a cat or dog and the parasitic invertebrate pest is a flea, tick or mite. 
ili N-oksida ili njihovih soli, za uporabu u zaštiti životinja od parazitskih nametnika beskralješnjaka, pri čemu se tvar primjenjuje oralno, životinja koju treba zaštititi je mačka ili pas, a parazitski nametnik beskralješnjak je buha, krpelj ili šugarac.
an antigen-specific targeting domain; 
(i) -antigen-specifičnu ciljajuću domenu;
H-indazole-3-carboxamide compounds according to claim 3, wherein Ra and Ra', equal or different each other, is a bromine atom, a hydroxy group; a C1-C3 alkoxy group; or an unsaturated carbocyclic or heterocyclic ring, having 6 members, optionally substituted by one or two substituents selected from the group consisting of halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, -NR1R2 and -COOH; and R1 and R2 are independently a hydrogen atom, a C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, and a phenyl group. 
Spojevi 1H-indazol-3-karboksamida prema zahtjevu 3, naznačeni time, da su svaki od R, i R, međusobno isti ili različiti, sljedeći: atom broma; hidroksi skupina; Ci-C3 alkoksi-skupina; ili nezasićeni karbociklički ili heterociklički prsten koji ima 6 članova, opcijski supstituiran s jednim ili dva supstituenta odabrana iz skupine koju čine halogen, hidroksi, C;-C> alkil, C,-Cs alkoksi, -NR;R2i -COOH; i R; 1 R, su neovisno vodikov atom, C1-C, alkil-skupina, C2-Ca alkenil-skupina, C,-C, alkinil-skupina i fenil-skupina.
wherein the compound of formula (IIIb) is present in a pharmaceutical composition. The pharmaceutical composition according to claim 1, wherein the compound has an effect on mutant CFTR protein, wherein said CFTR mutation is a mutation AF508-CFTR, or another mutation of class II, and wherein a mutation AF508-CFTR, or another mutation of class II are involved in CFTR protein malfunction. 
Tvar za uporabu u skladu s patentnim zahtjevom 1 ili 2 ili 3, pri čemu ona ima učinak na mutirani CFTR protein, pri čemu je navedena mutacija CFTR mutacija ∆F508-CFTR, ili druga mutacija klase II i pri čemu su mutacija ∆F508-CFTR, ili druga mutacija klase II uključene u nepravilnost funkcije CFTR proteina.
A method for the preparation of a polypeptide according to claim 1 comprising: providing a nucleic acid molecule comprising a nucleic acid sequence encoding the polypeptide; 
pripremu molekula nukleinske kiseline koji sadrži sekvencu nukleinske kiseline koja kodira polipeptid sukladno bilo kojem od patentnih zahtjeva 1-3;
The invention further relates to an air-tight covering to be used with a method described in the foregoing. 
Izum se, nadalje, odnosi na neprodušan pokrov koji se upotrebljava u gore opisanom postupku.
wherein is any structure of the following formula group [4]: 
Z! je bilo koja struktura prema slijedećoj skupini formula [4]:
The handgrips 76 for opening the packaging are provided in the outer parts 62. 
Dijelovi za zahvaćanje rukom pri otvaranju pakiranja predviđeni su na vanjskim dijelovima 62.
the variable light chain sequence of SEQ ID NO: 88 and variable heavy chain sequence of SEQ ID NO: 102; 
(d) varijabilno područje slabog lanca od sekvence SEQ ID NO: 88, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 102;
Thus the invention provides a method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and then (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other. 
Imunogeni pripravak koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, naznačen time da je za uporabu u postupku imunizacije subjekta protiv virusa influence koji sadrži korake (i) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, te zatim (11) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz drugog klada H5 virusa influence A, pri čemu su prvi i drugi klad međusobno različiti, te gdje:
System according to any of the preceding claims, wherein the RFID readers (7) comprise rechargeable batteries. 
Sustav u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu RF oznake (6) sadrže dugotrajne ili punjive baterije.
a bispecific antibody, wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 3, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 7, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 9; 
bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 3, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 7, a treći polipeptid i četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 9;
Of the four human IL-18BP (hIL-18BP) isoforms, isoforms a and c are known to have a neutralizing capacity for IL-18. 
Od četiri spomenuta ljudska izooblika (HL-18BP izooblici), a i c imaju kapacitet neutraliziranja proteina IL-18.
Further devices representative of the state of the prior art are described in WO 94/28782, US 4,877,033, US 5,313,934, and US 5,320,091 . 
Daljnji uređaji koji pokazuju stanje tehnike su opisani u WO 94/28782, US 4,877,033, US 5,313,934 1 US 5,320,091.
is C1-C10 linear, branched, or cyclic alkyl substituted by from 1 to 21 halogen atoms chosen from -F, -Cl, -Br, or -I; 
je C1-C10 nerazgranati, razgranati ili prstenasti alkil supstituiran s od 1 do 21 atoma halogena, koje se bira između -F, -Cl, -Br ili -I;
with the exception of the following prodrug conjugates: wherein m is an integer from 200 to 250 and n is an integer from 100 to 125; 
Predlijek, naznačen time, da je odabran iz skupine koju čine: pri čemu je m cijeli broj od 200 do 250, dok je n cijeli broj od 100 do 125;
A compound according to Claim 1, wherein R1 is 2'-OR, where R is H, methyl, ethyl or isopropyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R1 2′-OR, gdje je R H, metil, etil ili izopropil.
It is possible to grind the mineral material such that from 20 to 70 wt %, preferably from 36 to 68 wt %, more preferably from 40 to 60 wt %, e.g. 50 wt % of the at least one mineral material particles have a particle size of <2 um after step c). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da od 20 do 70 % tež., poželjno od 36 do 68 % tež., poželjnije od 40 do 60 % tež., npr. 50 % tež. čestica najmanje jednog mineralnog materijala imaju veličinu čestica od < 2 um nakon koraka c).
providing a second cation exchange resin and a second anion exchange resin, wherein the second cation exchange resin is regenerated in acid form, and wherein the second anion exchange resin is regenerated in alkali form; and contacting the sweet juice composition with the second cation exchange resin and the second anion exchange resin to produce a second sweet juice composition. 
Postupak sukladno bilo kojem od zahtjeva 1 do 5, nadalje obuhvaća: pružanje smole za drugu izmjenu kationa i smole za drugu izmjenu aniona, pri čemu je smola za drugu izmjenu kationa regenerirana u obliku kiseline,, i pri čemu je smola za drugu izmjenu aniona regenerirana u alkalnom obliku; i spajanje satava slatkog soka sa smolom za drugu izmjenu kationa i smolom za drugu izmjenu aniona kako bi se proizvelo drugi sastav slatkog soka.
The composite panel as claimed in claim 1, wherein said transparent to light material is provided with light reflection properties or treated with a coating having light reflection properties. 
Ploča prema zahtjevu 1, naznačena time što spomenuti materijal proziran za svijetlost ima svojstvo reflektiranja svijetlosti 1li je tretiran premazom koji ima svojstvo reflektiranja svijetlosti.
Optionally, a fat such as an oil (vegetable oil, corn oil, olive oil, grape seed oil, nut oil or fruit oil), butter, shortening, artificial lipid, synthetic fat, or a fat substitute such as olestra is also present. 
Pekarska kompozicija iz patentnog zahtjeva 6, gdje navedeni kruh obuhvaća žemlju, kiflu, ili pecivo. Pekarska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 4, koja dalje sadrži ulje, putar, masnoću, umjetni lipid, sintetičku mast, ili zamjenu za mast.
A compound according to claim 1, wherein W is NR7 and wherein R7 and R5 together with the corresponding N atom and C atom to which they are attached form a substituted or unsubstituted pyrrolidine group. 
Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, što je W NR; i gdje R; i Rs skupa sa odgovarajućim N atomom i C atomom za koje su prikačeni formiraju supstituiranu ili nesupstituiranu pirolidinsku grupu.
Mice heterozygous for a first insertion of human λ sequences (hVλ3-12-Vλ3-1 and hJλ1, FIG. 
(a) susjedne sekvence lokusa humanog lakog 2 lanca koja se proteže od VA3-12 do V23-1;
optional sweetener; and wherein the preservative comprises methyl paraben, ethyl paraben and benzyl alcohol. 
(g) izborno sladilo; te gdje konzervans sadrži metilparaben, etilparaben i benzil-alkohol.
The humidity content is determined according to DIN 52 183. 
Sadržaj vlage se određuje prema DIN 52 183.
a heavy chain comprising a sequence of SEQ ID NO: 58 and a light chain comprising a sequence of SEQ ID NO: 66; or 
Protutijelo prema zahtjevu 2, naznačeno time, da protutijelo obuhvaća teški lanac koji se sastoji od sekvence od SEQ ID NO: 53 i laki lanac koji se sastoji od sekvence od SEQ ID NO: 60.
To a solution of 2,4-difluorobenzonitrile (10 g, 72 mmol) dissolved in THF (20 mL), and DMF (40 mL) was added 1,2,4-triazole sodium derivative (6.3 g, 70 mmol) and the mixture was stirred at 90° C. for 3 h, filtered and concentrated. 
U otopinu 2,4difluorobenzonitrila (10 g, 72 mmol) otopljenog u THF (20 mL) i DMF (40 mL) dodan je 1,2,4-triazol natrij derivat (6.3 g, 70 mmol) i smjesa je miješana na 90*C 3 sata, filtrirana i koncentrirana.
compressing the primary bag in such a way as to extract the blood component from the primary bag and transfer it to the collecting satellite bag, 
kompresije primarne vreće (1) na takav način da se ekstrahira komponenta krvi iz primarne vreće (1) i prenese na zbirnu satelitsku vreću (3),
The method of claims 1-12, wherein the vaccine comprises one or more of: killed whole cell Bordetella pertussis (Pw); two or more acellular pertussis components (Pa); one or more conjugates of a carrier protein and a capsular saccharide of a bacterium selected from the group Neisseria meningitidis type A, Neisseria Meningitidis type C, Neisseria meningitidis type W and Neisseria meningitidis type Y; a Neisseria meningitidis type B (MenB) outer membrane vesicle or LOS or a conjugated MenB capsular saccharide, or derivative thereof; a Vi saccharide from Salmonella typhi conjugated to a carrier protein; or an antigen from Hepatitis A. 
Postupak u skladu s patentnim zahtjevima 1-12, naznačen time što cjepivo sadrži jedno ili više od: umrtvljenih cijelih stanica bakterije Bordetella pertussis (Pw); dvije ili više nestaničnih komponenata uzročnika hripavca (Pa); jednog ili više konjugata proteinskog nosača s kapsularnim saharidom bakterije koju se bira iz skupine koju čine Neisseria meningitidis ip A, Neisseria meningitidis tip C, Neisseria meningitidis tip W 1 Neisseria meningitidis tip X; vezikule od vanjske membrane ili LOS ili konjugiranog kapsularnog saharida MenB iz bakterije Neisseria meningitidis tip B (MenB), ili njegovog derivata; saharida Vi iz bakterije Salmonella typhi konjugiranog na proteinski nosač; ili antigena virusa Hepatitisa A.
The liquefied gas treatment system according to claim 6, further comprising a cooler configured to cool the BOG, which is liquefied by the heat exchanger and is supplied to the decompressing means, by exchanging heat with the liquid component of the BOG which is decompressed to the gas-liquid mixed state while passing through the decompressing means. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što pomoćna linija za slanje LNG (L24) dodatno sadrži grijač (47), podešen za podešavanje temperature goriva, čiji se metanski broj podešava u separatoru plina od tekućine do vrijednosti potrebne za pomoćni motor.
The floating lake system of claim 9, wherein the rigid materials of the frame components comprise metal, metal alloys, plastics, wood, concrete, or combinations thereof. 
Sustav plutajućeg jezera (1) prema zahtjevu 22, naznačen time što kruti materijali komponenti okvira sadrže metal, legure metala, plastiku, drvo, beton ili njihove kombinacije.
Forms which are frequently mentioned are sartans, such as candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan or valsartan. The present invention relates to telmisartan. 
Sartan za uporabu prema zahtjevu 1, naznačen time, da je sartan odabran iz skupine koju čine: kandesartan, eprosartan, irbesartan, losartan, tazosartan, telmisartan, valsartan i njihova farmaceutski prihvatljiva sol.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) ciprodinil.
The polypeptide of any one of claims 1-3 wherein the polypeptide elicits a protective immune response in a mammalian host against strains of C.difficile. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što polipeptid izaziva zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
coupling the 2-3 eptifibatide sequence and the 4-6 eptifibatide sequence through attachment of the Gly of the 2-3 eptifibatide sequence to the Asp of the 4-6 eptifibatide sequence, thereby forming a 2-6 eptifibatide sequence of the formula: 
P:-Asp(O-P>2)-Trp-Pro-OH; kopuliranje fragmenta 2-3 eptifibatida i fragmenta 4-6 eptifibatida putem vezivanja Gly ostatka fragmenta 2-3 eptifibatida na Asp ostatak fragmenta 4-6 eptifibatida, da na taj način nastane fragment 2-6 eptifibatida formule:
The pharmaceutical composition of claim 16, wherein crystalline form I of abexinostat tosylate is characterized in that it has a solid-state 13C CP/MAS NMR spectrum having the following peaks (expressed in ppm±0.2 ppm): Peak 
Kristalni oblik I tozilata abeksinostata u skladu s patentnim zahtjevom 8, naznačen time što ima 13C CP/MAS NMR spektar čvrstog stanja sa slijedećim vršnim vrijednostima (izraženo u ppm ± 0,2 ppm):
According to a further aspect of the invention a liquid coating composition is provided, capable of curing by heat activation. 
U skladu s daljnjim oblikom izuma osiguran je tekući premaz, koji se može otvrdnuti toplinskom aktivacijom.
represents a benzene ring or a naphthalene; the ring being optionally substituted by 1 to 4 substituents selected from a C1-3 alkyl group, a C1-2 perhalogenated alkyl group, a C3-4 cycloalkyl group, a C3-4 cycloalkyl-C1-3 alkyl group, a halogen atom, a hydroxyl group, a nitro, a cyano, an amino, a C1-3 alkoxy group optionally substituted by a C3-4 cycloalkyl group, a C1-2 perhalogenated alkoxy group or a C1-3 alkylsulfonyl group; and/or 
R2 predstavlja benzenski ili naftalenski prsten, gdje je navedeni prsten izborno supstituiran s 1 do 4 supstituenta, koje se bira između C,., alkilne skupine, Ci> perhalogenirane alkilne skupine, C3a cikloalkilne skupine, Ca cikloalkil-C;.3 alkilne skupine, atoma halogena, hidroksilne skupine, nitro, cijano, amino, Cia alkoksi skupine, izborno supstituirane s Caa cikloalkilnom skupinom, C,2 perhalogeniranom alkoksi skupinom ili C,3 alkilsulfonilnom skupinom; R3 predstavlja atom vodika ili atom halogena; R4 predstavlja atom vodika;
an outlet for exit of an off-gas from the chamber; 
otvor za izlaz oslobođenog plina iz komore;
This device comprises an injection-like structure with a plunger-cylinder. 
Ova naprava ima konstrukciju koja naliči na injekciju s klipom i cilindrom.
The piezoelectric power supply converter as claimed in claim 14, wherein said first piezoelectric element is a piezoelectric-oscillator or an insulating piezoelectric oscillator.. 
Piezoelektrični pretvornik napajanja prema zahtjevu 8, naznačen time da navedeni drugi piezoelektrični element (13) je piezoelektrični kondenzator.
providing a hydrophilic solvent; 
(i) dobivanje hidrofilnog otapala;
In a further aspect of the present invention there is provided the use of an anti-NOGO antibody (e.g. an anti-NOGO antibody comprising the CDRs set forth herein) in the manufacture of an intravenously administrable medicament for the treatment of stroke (particularly ischemic stroke), brain injury, spinal cord injury, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease, multiple sclerosis and in particular Alzheimer's disease in a human patient. 
Upotreba protutijela protiv Nogo-A, ili njegovog funkcionalnog fragmenta ili analoga, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, u pripravi medikamenta za sprječavanje neurodegeneracije iili poticanje funkcionalnog oporavka kod ljudskog pacijenta koji boluje, ili je u opasnosti od pojave, inzulta, traumatske ozljede mozga, ozljede kralježničke moždine, Alzheimerove bolesti, fronto-temporalnih demencija (tauopatija), periferne neuropatije, Parkinsonove bolesti, Huntingtonove bolesti ili multiple skleroze.
In the field of bone cement the shrinkage creates porous structures between the bone cement and implant cement. 
U području cementa za kost, skupljanje uzrokuje nastajanje poroznih struktura u cementu za kost i cementu implanta.
The salt of Claim 8 further characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -96.5, -104.4, -106.3, and -154.5 ppm. 
Sol iz Zahtjeva 10, nadalje, naznačena time, da spektar nuklearne rezonance krutog fluorina-19 MAS pokazuje signale na-96,5, -104.4, -106.3, i -154.5 ppm
The a-glucosidase inhibitors competitively inhibit digestive enzymes such as a-amylase, maltase, a-dextrinase, sucrase, etc. in the pancreas and or small intestine. 
Inhibitori a-glukozidaze kompetitivno inhibiraju probavne enzime poput a-amilaze, maltaze, adekstrinaze, saharaze i slično, u pankreasu ili tankom crijevu.
The oil according to claim 2 wherein said flavourings are selected from the group consisting of natural flavouring, nature-identical flavouring, essential cereal oil and essential fruit oil, and mixtures thereof. 
Ulje prema zahtjevu 4, naznačeno time, da spomenuti aromatski dodaci su sljedeći: prirodni aromatski dodaci, aromatski dodaci istovjetni prirodnima, esencijalna ulja žitarica i esencijalna voćna ulja te njihove mješavine.
The mobile station apparatus according to any of claims 1 to 4, wherein DVRBs with consecutive DVRB numbers are allocated in the first allocation. 
Integrirani krug sukladno jednom od zahtjeva 1 do 5, naznačen time da su u prvoj dodjeli DVRB-ovi s uzastopnim DVRB brojevima dodijeljeni aparatu mobilnoj stanici.